<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40"><head><meta http-equiv=Content-Type content="text/html; charset=us-ascii"><meta name=Generator content="Microsoft Word 15 (filtered medium)"><!--[if !mso]><style>v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style><![endif]--><style><!--
/* Font Definitions */
@font-face
{font-family:Helvetica;
panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
{font-family:Wingdings;
panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Verdana;
panose-1:2 11 6 4 3 5 4 4 2 4;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0cm;
margin-bottom:.0001pt;
font-size:11.0pt;
font-family:"Calibri",sans-serif;
mso-fareast-language:EN-US;}
h1
{mso-style-priority:9;
mso-style-link:"Heading 1 Char";
mso-margin-top-alt:auto;
margin-right:0cm;
mso-margin-bottom-alt:auto;
margin-left:0cm;
font-size:24.0pt;
font-family:"Times New Roman",serif;
font-weight:bold;}
h2
{mso-style-priority:9;
mso-style-link:"Heading 2 Char";
mso-margin-top-alt:auto;
margin-right:0cm;
mso-margin-bottom-alt:auto;
margin-left:0cm;
font-size:18.0pt;
font-family:"Times New Roman",serif;
font-weight:bold;}
h3
{mso-style-priority:9;
mso-style-link:"Heading 3 Char";
margin-top:2.0pt;
margin-right:0cm;
margin-bottom:0cm;
margin-left:0cm;
margin-bottom:.0001pt;
page-break-after:avoid;
font-size:12.0pt;
font-family:"Calibri Light",sans-serif;
color:#1F4D78;
mso-fareast-language:EN-US;
font-weight:normal;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
{mso-style-priority:99;
mso-style-link:"Body Text Char";
mso-margin-top-alt:auto;
margin-right:0cm;
mso-margin-bottom-alt:auto;
margin-left:0cm;
font-size:12.0pt;
font-family:"Times New Roman",serif;
mso-fareast-language:EN-US;}
p.MsoSubtitle, li.MsoSubtitle, div.MsoSubtitle
{mso-style-priority:11;
mso-style-link:"Subtitle Char";
margin-top:0cm;
margin-right:0cm;
margin-bottom:8.0pt;
margin-left:0cm;
font-size:11.0pt;
font-family:"Calibri",sans-serif;
color:#5A5A5A;
letter-spacing:.75pt;
mso-fareast-language:EN-US;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:#0563C1;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:#954F72;
text-decoration:underline;}
p
{mso-style-priority:99;
mso-margin-top-alt:auto;
margin-right:0cm;
mso-margin-bottom-alt:auto;
margin-left:0cm;
font-size:12.0pt;
font-family:"Times New Roman",serif;}
address
{mso-style-priority:99;
mso-style-link:"HTML Address Char";
margin:0cm;
margin-bottom:.0001pt;
font-size:12.0pt;
font-family:"Times New Roman",serif;
font-style:italic;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
{mso-style-priority:34;
margin-top:0cm;
margin-right:0cm;
margin-bottom:8.0pt;
margin-left:36.0pt;
mso-add-space:auto;
line-height:105%;
font-size:11.0pt;
font-family:"Calibri",sans-serif;
mso-fareast-language:EN-US;}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParagraphCxSpFirst
{mso-style-priority:34;
mso-style-type:export-only;
margin-top:0cm;
margin-right:0cm;
margin-bottom:0cm;
margin-left:36.0pt;
margin-bottom:.0001pt;
mso-add-space:auto;
line-height:105%;
font-size:11.0pt;
font-family:"Calibri",sans-serif;
mso-fareast-language:EN-US;}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListParagraphCxSpMiddle
{mso-style-priority:34;
mso-style-type:export-only;
margin-top:0cm;
margin-right:0cm;
margin-bottom:0cm;
margin-left:36.0pt;
margin-bottom:.0001pt;
mso-add-space:auto;
line-height:105%;
font-size:11.0pt;
font-family:"Calibri",sans-serif;
mso-fareast-language:EN-US;}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagraphCxSpLast
{mso-style-priority:34;
mso-style-type:export-only;
margin-top:0cm;
margin-right:0cm;
margin-bottom:8.0pt;
margin-left:36.0pt;
mso-add-space:auto;
line-height:105%;
font-size:11.0pt;
font-family:"Calibri",sans-serif;
mso-fareast-language:EN-US;}
span.EmailStyle17
{mso-style-type:personal-compose;
font-family:"Calibri",sans-serif;
color:windowtext;}
span.Heading1Char
{mso-style-name:"Heading 1 Char";
mso-style-priority:9;
mso-style-link:"Heading 1";
font-family:"Times New Roman",serif;
mso-fareast-language:EN-ZW;
font-weight:bold;}
span.Heading2Char
{mso-style-name:"Heading 2 Char";
mso-style-priority:9;
mso-style-link:"Heading 2";
font-family:"Times New Roman",serif;
mso-fareast-language:EN-ZW;
font-weight:bold;}
span.Heading3Char
{mso-style-name:"Heading 3 Char";
mso-style-priority:9;
mso-style-link:"Heading 3";
font-family:"Calibri Light",sans-serif;
color:#1F4D78;}
span.HTMLAddressChar
{mso-style-name:"HTML Address Char";
mso-style-priority:99;
mso-style-link:"HTML Address";
font-family:"Times New Roman",serif;
mso-fareast-language:EN-ZW;
font-style:italic;}
p.msonormal0, li.msonormal0, div.msonormal0
{mso-style-name:msonormal;
mso-style-priority:99;
mso-margin-top-alt:auto;
margin-right:0cm;
mso-margin-bottom-alt:auto;
margin-left:0cm;
font-size:12.0pt;
font-family:"Times New Roman",serif;}
span.BodyTextChar
{mso-style-name:"Body Text Char";
mso-style-priority:99;
mso-style-link:"Body Text";
font-family:"Times New Roman",serif;}
span.SubtitleChar
{mso-style-name:"Subtitle Char";
mso-style-priority:11;
mso-style-link:Subtitle;
font-family:"Calibri",sans-serif;
color:#5A5A5A;
letter-spacing:.75pt;}
span.style30
{mso-style-name:style30;}
span.updated-wrap
{mso-style-name:updated-wrap;}
span.updated-text
{mso-style-name:updated-text;}
span.vjs-control-text
{mso-style-name:vjs-control-text;}
span.vjs-current-time-display
{mso-style-name:vjs-current-time-display;}
span.vjs-duration-display
{mso-style-name:vjs-duration-display;}
span.link600907a1
{mso-style-name:link__600907a1;}
span.pricechangea4e5ebde
{mso-style-name:pricechange__a4e5ebde;}
span.percentchange4644dd7b
{mso-style-name:percentchange__4644dd7b;}
span.nenh5bclitmmlhqori6r
{mso-style-name:nenh5bclitmmlhq_ori6r;}
span.z-TopofFormChar
{mso-style-name:"z-Top of Form Char";
mso-style-priority:99;
mso-style-link:"z-Top of Form";
font-family:"Arial",sans-serif;
display:none;}
span.3vdg7tz3nbnbjk7gdr2y2
{mso-style-name:_3vdg7tz3nbnbjk7gdr2y2_;}
span.2ml6cep2ydeajtymouc70a
{mso-style-name:_2ml6cep2ydeajtymouc70a;}
span.z-BottomofFormChar
{mso-style-name:"z-Bottom of Form Char";
mso-style-priority:99;
mso-style-link:"z-Bottom of Form";
font-family:"Arial",sans-serif;
display:none;}
.MsoChpDefault
{mso-style-type:export-only;
font-family:"Calibri",sans-serif;
mso-fareast-language:EN-US;}
@page WordSection1
{size:612.0pt 792.0pt;
margin:72.0pt 72.0pt 72.0pt 72.0pt;}
div.WordSection1
{page:WordSection1;}
/* List Definitions */
@list l0
{mso-list-id:1940411854;
mso-list-template-ids:366645300;}
@list l0:level1
{mso-level-number-format:bullet;
mso-level-text:\F0B7;
mso-level-tab-stop:36.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:72.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l0:level3
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:108.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level4
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:144.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level5
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:180.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level6
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:216.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level7
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:252.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level8
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:288.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level9
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:324.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
ol
{margin-bottom:0cm;}
ul
{margin-bottom:0cm;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]--></head><body lang=EN-ZW link="#0563C1" vlink="#954F72"><div class=WordSection1><div align=center><table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=916 style='width:687.2pt;border-collapse:collapse;border:none'><tr><td width=910 colspan=4 valign=top style='width:682.8pt;border:solid white 1.0pt;border-bottom:none;padding:0cm 5.4pt 0cm 5.4pt'></td><td width=6 style='width:4.4pt;border:none;border-top:solid white 1.0pt;padding:0cm 0cm 0cm 0cm'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'> <o:p></o:p></span></p></td></tr><tr><td width=910 colspan=4 valign=top style='width:682.8pt;border-top:none;border-left:solid white 1.0pt;border-bottom:none;border-right:solid white 1.0pt;background:#F2F2F2;padding:0cm 5.4pt 0cm 5.4pt'><p class=MsoNormal style='text-indent:33.35pt;line-height:106%'><span lang=EN-US><a href="https://bullszimbabwe.com/"><span lang=EN-ZW style='font-family:"Verdana",sans-serif;color:windowtext;mso-fareast-language:EN-ZW;text-decoration:none'><img border=0 width=246 height=120 id="Picture_x0020_9" src="cid:image001.png@01D6FBBC.CB8E91B0"></span></a></span><span lang=EN-US style='font-family:"Verdana",sans-serif'><o:p></o:p></span></p></td><td width=6 style='width:4.4pt;border:none;padding:0cm 0cm 0cm 0cm'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'> <o:p></o:p></span></p></td></tr><tr><td width=910 colspan=4 valign=top style='width:682.8pt;border-top:none;border-left:solid white 1.0pt;border-bottom:none;border-right:solid white 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'><p class=MsoNormal style='margin-left:32.1pt;text-indent:7.5pt;line-height:105%'><b><span lang=EN-US style='font-family:"Verdana",sans-serif;color:#002060'><o:p> </o:p></span></b></p><p class=MsoNormal><span lang=EN-US><a href="http://www.bullszimbabwe.com"><span style='text-decoration:none'>Bullszimbabwe.com </span></a> <a href="mailto:info@bulls.co.zw?subject=View%20and%20Comments"><span style='text-decoration:none'>Views & Comments</span></a> <a href="https://bullszimbabwe.com/category/blogs/bullish-thoughts/"><span style='text-decoration:none'>Bullish Thoughts</span></a> <a href="http://www.twitter.com/BullsBears2010"><span style='text-decoration:none'>Twitter</span></a> <a href="https://www.facebook.com/BullsBearsZimbabwe"><span style='text-decoration:none'>Facebook</span></a> <a href="http://www.linkedin.com/pub/bulls-n-bears-zimbabwe/57/577/72"><span style='text-decoration:none'>LinkedIn</span></a> <a href="https://chat.whatsapp.com/CF6wllAfScU9Wr6dXxoQnO"><span style='text-decoration:none'>WhatsApp</span></a> <a href="mailto:info@bulls.co.zw?subject=Unsubscribe"><span style='text-decoration:none'>Unsubscribe</span></a></span><span lang=EN-US><o:p></o:p></span></p></td><td width=6 style='width:4.4pt;border:none;padding:0cm 0cm 0cm 0cm'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'> <o:p></o:p></span></p></td></tr><tr><td width=910 colspan=4 valign=top style='width:682.8pt;border-top:none;border-left:solid white 1.0pt;border-bottom:none;border-right:solid white 1.0pt;background:#F2F2F2;padding:0cm 5.4pt 0cm 5.4pt'><p class=MsoSubtitle style='margin-left:32.1pt;text-indent:7.5pt;line-height:105%'><span class=style30><b><span lang=EN-US style='font-family:"Verdana",sans-serif;color:black'><o:p> </o:p></span></b></span></p></td><td width=6 style='width:4.4pt;border:none;padding:0cm 0cm 0cm 0cm'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'> <o:p></o:p></span></p></td></tr><tr><td width=910 colspan=4 valign=top style='width:682.8pt;border-top:none;border-left:solid white 1.0pt;border-bottom:none;border-right:solid white 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'><p class=MsoNormal style='line-height:105%'><span class=style30><b><span lang=EN-US style='font-family:"Verdana",sans-serif;color:#1F497D'>Coronavirus Global Updates, Feb 05:::: Russia-China Vaccine Partnership; India Covax Haul: Virus Update</span></b></span><b><span lang=EN-US style='font-family:"Verdana",sans-serif'><o:p></o:p></span></b></p></td><td width=6 style='width:4.4pt;border:none;padding:0cm 0cm 0cm 0cm'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'> <o:p></o:p></span></p></td></tr><tr><td width=910 colspan=4 valign=top style='width:682.8pt;border-top:none;border-left:solid white 1.0pt;border-bottom:none;border-right:solid white 1.0pt;background:#F2F2F2;padding:0cm 5.4pt 0cm 5.4pt'><p class=MsoNormal style='line-height:105%'><span class=style30><b><span lang=EN-US style='font-family:"Verdana",sans-serif'><o:p> </o:p></span></b></span></p></td><td width=6 style='width:4.4pt;border:none;padding:0cm 0cm 0cm 0cm'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'> <o:p></o:p></span></p></td></tr><tr style='height:3.0pt'><td width=910 colspan=4 valign=top style='width:682.8pt;border-top:none;border-left:solid white 1.0pt;border-bottom:none;border-right:solid white 1.0pt;padding:0cm 5.4pt 0cm 5.4pt;height:3.0pt'><p class=MsoNormal style='text-indent:33.35pt;line-height:105%'><span lang=EN-US><a href="https://www.nicozdiamond.co.zw/"><b><span lang=EN-ZW style='font-family:"Verdana",sans-serif;color:windowtext;mso-fareast-language:EN-ZW;text-decoration:none'><img border=0 width=810 height=268 id="Picture_x0020_8" src="cid:image003.jpg@01D6FBBD.AD5B4980"></span></b></a></span><span class=style30><b><span lang=EN-US style='font-family:"Verdana",sans-serif'><o:p></o:p></span></b></span></p></td><td width=6 style='width:4.4pt;border:none;padding:0cm 0cm 0cm 0cm;height:3.0pt'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'> <o:p></o:p></span></p></td></tr><tr style='height:10.05pt'><td width=910 colspan=4 valign=top style='width:682.8pt;border-top:none;border-left:solid white 1.0pt;border-bottom:none;border-right:solid white 1.0pt;background:#F2F2F2;padding:0cm 5.4pt 0cm 5.4pt;height:10.05pt'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'><o:p> </o:p></span></p></td><td width=6 style='width:4.4pt;border:none;padding:0cm 0cm 0cm 0cm;height:10.05pt'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'> <o:p></o:p></span></p></td></tr><tr style='height:10.05pt'><td width=910 colspan=4 rowspan=3 valign=top style='width:682.8pt;border-top:none;border-left:solid white 1.0pt;border-bottom:none;border-right:solid white 1.0pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.05pt'><h1 style='line-height:33.75pt;background:white'><span lang=EN-US style='font-size:11.0pt;font-family:"Verdana",sans-serif;mso-fareast-language:EN-US'>Zimbabwe COVID19 Update</span><span lang=EN-US style='font-size:11.0pt;font-family:"Verdana",sans-serif;mso-fareast-language:EN-US'><o:p></o:p></span></h1><h1 style='mso-margin-top-alt:7.5pt;margin-right:0cm;margin-bottom:0cm;margin-left:0cm;margin-bottom:.0001pt;line-height:106%;background:white'><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black;mso-fareast-language:EN-US;font-weight:normal'>COVID-19 update: As at 04 February 2021, Zimbabwe had 34 171 confirmed cases, including 27 759 recoveries and 1 288 deaths.<o:p></o:p></span></h1><h1 style='mso-margin-top-alt:7.5pt;margin-right:0cm;margin-bottom:0cm;margin-left:0cm;margin-bottom:.0001pt;line-height:106%;background:white'><span style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black'><img border=0 width=666 height=893 id="Picture_x0020_10" src="cid:image004.jpg@01D6FBBD.AD5B4980" alt=Image></span><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black;mso-fareast-language:EN-US'><o:p></o:p></span></h1><h1 style='mso-margin-top-alt:7.5pt;margin-right:0cm;margin-bottom:0cm;margin-left:0cm;margin-bottom:.0001pt;line-height:106%;background:white'><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black;mso-fareast-language:EN-US'><o:p> </o:p></span></h1><h1 style='mso-margin-top-alt:0cm;margin-right:0cm;margin-bottom:15.0pt;margin-left:0cm;line-height:106%;background:white;vertical-align:baseline'><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black;letter-spacing:-.3pt;mso-fareast-language:EN-US'>Russia-China Vaccine Partnership; India Covax Haul: Virus Update<o:p></o:p></span></h1><h3 style='mso-margin-top-alt:9.25pt;margin-right:0cm;margin-bottom:9.25pt;margin-left:0cm;line-height:106%;background:white;vertical-align:baseline'><b><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black'>Russian Vaccine Team in Talks With China on Combination Trial <o:p></o:p></span></b></h3><p style='margin:0cm;margin-bottom:.0001pt;line-height:106%;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit'><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black;mso-fareast-language:EN-US'>Fresh off global validation of their Covid-19 vaccine’s extraordinary effectiveness, Russian developers are <a href="https://www.bloomberg.com/news/articles/2021-02-05/russian-vaccine-team-in-talks-with-china-on-combination-trial" target="_blank" title="Russian Vaccine Team in Talks With China on Combination Trial"><span style='color:black;border:none windowtext 1.0pt;padding:0cm;text-decoration:none'>in talks</span></a> with China’s CanSino Biologics Inc. to test a combined regimen of their shots to better protect against new virus strains, according to people with knowledge of the matter.<o:p></o:p></span></p><p style='mso-margin-top-alt:22.5pt;margin-right:0cm;margin-bottom:22.5pt;margin-left:0cm;line-height:106%;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit'><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black;mso-fareast-language:EN-US'>The Russian Direct Investment Fund, a partner in the Sputnik V vaccine program, forged a preliminary agreement with the Tianjin-based vaccine developer and Petrovax Pharm Llc, owned by billionaire Vladimir Potanin, to conduct tests in Russia, four people said, declining to be identified as the information isn’t public. Petrovax is Cansino’s Russian partner.<o:p></o:p></span></p><h3 style='mso-margin-top-alt:9.25pt;margin-right:0cm;margin-bottom:9.25pt;margin-left:0cm;line-height:106%;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit' id=israel-extends-lockdown-will-ease-some-restrictions-from-sunday-423-pm-hk><b><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black'>Israel Extends Lockdown, Will Ease Some Restrictions >From Sunday <o:p></o:p></span></b></h3><p style='margin:0cm;margin-bottom:.0001pt;line-height:106%;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit'><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black;mso-fareast-language:EN-US'>Israel’s cabinet voted overnight to <a href="https://www.bloomberg.com/news/articles/2021-02-05/israel-extends-lockdown-will-ease-some-restrictions-from-sunday" target="_blank" title="Israel Extends Lockdown, Will Ease Some Restrictions From Sunday"><span style='color:black;border:none windowtext 1.0pt;padding:0cm;text-decoration:none'>extend the country’s lockdown</span></a> to Sunday morning from Friday, and agreed to begin gradually reopening parts of the economy next week.<o:p></o:p></span></p><p style='mso-margin-top-alt:22.5pt;margin-right:0cm;margin-bottom:22.5pt;margin-left:0cm;line-height:106%;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit'><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black;mso-fareast-language:EN-US'>Starting Feb. 7, restrictions on movement will be lifted while certain businesses will be able to reopen. Ministers will meet Sunday to further discuss the country’s exit plan from its third lockdown.<o:p></o:p></span></p><h3 style='mso-margin-top-alt:9.25pt;margin-right:0cm;margin-bottom:9.25pt;margin-left:0cm;line-height:106%;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit' id=hungarys-most-vulnerable-to-get-vaccine-by-midmarch-orban-404-pm-hk><b><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black'>Hungary’s Most Vulnerable to Get Vaccine By Mid-March: Orban <o:p></o:p></span></b></h3><p style='margin:0cm;margin-bottom:.0001pt;line-height:106%;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit'><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black;mso-fareast-language:EN-US'>Hungary could gradually start its <a href="https://www.bloomberg.com/news/terminal/QO1MKWT0G1KZ" target="_blank" title="Hungary’s Most Vulnerable to Get Vaccine By Mid-March: Orban"><span style='color:black;border:none windowtext 1.0pt;padding:0cm;text-decoration:none'>return to normality</span></a> as soon as this spring with inoculation of the most exposed groups taking place by March 15, Prime Minister Viktor Orban said Friday. While research into Chinese shots is still ongoing, the use of Russia’s Sputnik V could potentially start next week, Orban told state radio station Kossuth in a weekly interview. Besides joint European Union procurement of shots produced by Moderna Inc. and Pfizer Inc., Hungary has approved AstraZeneca Plc’s vaccine, as well as ones from China and Russia.<br><br><o:p></o:p></span></p><h3 style='mso-margin-top-alt:9.25pt;margin-right:0cm;margin-bottom:9.25pt;margin-left:0cm;line-height:106%;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit' id=israels-pioneering-covid-vaccination-program-offers-key-lessons-344-pm-hk><b><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black'>Israel’s Pioneering Covid Vaccination Program Offers Key Lessons <o:p></o:p></span></b></h3><p style='mso-margin-top-alt:22.5pt;margin-right:0cm;margin-bottom:22.5pt;margin-left:0cm;line-height:106%;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit'><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black;mso-fareast-language:EN-US'>Israel, with the highest proportion of citizens vaccinated against Covid-19 in the world, found it took three weeks for the Pfizer Inc.-BioNTech SE shot to start curbing new cases and hospitalizations.<br><br>Researchers in the Middle Eastern country reported <a href="https://www.bloomberg.com/news/articles/2021-02-05/israel-s-pioneering-covid-vaccination-program-offers-key-lessons" target="_blank" title="Israel’s Pioneering Covid Vaccination Program Offers Key Lessons"><span style='color:black;border:none windowtext 1.0pt;padding:0cm;text-decoration:none'>preliminary observations</span></a> Wednesday from a national immunization program that began Dec. 20. Improvement in the number of new cases and hospitalized patients occurred 21 days following the vaccination campaign, the scientists said, noting that the real-life effect of vaccines may take longer than what was demonstrated in clinical trials.<br><br><o:p></o:p></span></p><h3 style='mso-margin-top-alt:9.25pt;margin-right:0cm;margin-bottom:9.25pt;margin-left:0cm;line-height:106%;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit' id=astrazeneca-applies-for-japan-vaccine-approval-report-258-pm-hk><b><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black'>AstraZeneca Applies for Japan Vaccine Approval: Report <o:p></o:p></span></b></h3><p style='margin:0cm;margin-bottom:.0001pt;line-height:106%;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit'><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black;mso-fareast-language:EN-US'>AstraZeneca <a href="https://www.bloomberg.com/news/terminal/QO1ML9DWX2Q3" target="_blank" title="AstraZeneca Applies for Japan Approval of Covid Vaccine: Nikkei"><span style='color:black;border:none windowtext 1.0pt;padding:0cm;text-decoration:none'>applied</span></a> to Japan’s health ministry Friday for approval for its Covid-19 vaccine, Nikkei reported, without attribution. The company still needs to submit clinical data in March, the report said.<br><br><o:p></o:p></span></p><h3 style='mso-margin-top-alt:9.25pt;margin-right:0cm;margin-bottom:9.25pt;margin-left:0cm;line-height:106%;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit' id=french-german-leaders-comment-on-lockdowns-242-pm-hk><b><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black'>French, German Leaders Comment on Lockdowns <o:p></o:p></span></b></h3><p style='margin:0cm;margin-bottom:.0001pt;line-height:106%;background:white;vertical-align:baseline'><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black;mso-fareast-language:EN-US'>French Prime Minister Jean Castex said it’s not possible to ease Covid-19 restrictions yet, but the situation <a href="https://www.bloomberg.com/news/articles/2021-02-04/france-says-new-lockdown-not-justified-at-the-moment" target="_blank" title="France Says New Lockdown Not Justified at the Moment (1)"><span style='color:black;border:none windowtext 1.0pt;padding:0cm;text-decoration:none'>doesn’t justify imposing</span></a> a fresh lockdown.<o:p></o:p></span></p><p style='mso-margin-top-alt:22.5pt;margin-right:0cm;margin-bottom:22.5pt;margin-left:0cm;line-height:106%;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit'><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black;mso-fareast-language:EN-US'>“We have kept the epidemic under control while preserving the economic and social life of our country as much as possible,” Castex said Thursday in a weekly news conference to update the nation on the health situation and examine whether current measures are effective.<o:p></o:p></span></p><p style='mso-margin-top-alt:22.5pt;margin-right:0cm;margin-bottom:22.5pt;margin-left:0cm;line-height:106%;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit'><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black;mso-fareast-language:EN-US'>Meanwhile, German Chancellor Angela Merkel said in an interview with RTL Media Group it’s still too soon to ease the lockdown in Europe’s largest economy, even as the pandemic shows signs of ebbing. She’ll meet regional German leaders next week to discuss whether to continue current restrictions, which include shuttered bars, restaurants and most retailers, beyond Feb. 14.<o:p></o:p></span></p><h3 style='mso-margin-top-alt:9.25pt;margin-right:0cm;margin-bottom:9.25pt;margin-left:0cm;line-height:106%;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit' id=lancet-study-recommends-weekly-testing-in-us-224-pm-hk><b><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black'>Lancet Study Recommends Weekly Testing in U.S. <o:p></o:p></span></b></h3><p style='margin:0cm;margin-bottom:.0001pt;line-height:106%;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit'><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black;mso-fareast-language:EN-US'>Until vaccines are widely available, weekly Covid-19 testing plus a two-week isolation period for positive cases may be the most cost-effective strategy to tackle the spread of the virus in the U.S. when transmission is high, a <a href="https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(21)00002-5/fulltext?utm_campaign=tlcoronavirus21&utm_content=153377515&utm_medium=social&utm_source=twitter&hss_channel=tw-27013292" target="_blank" title="Lancet study"><span style='color:black;border:none windowtext 1.0pt;padding:0cm;text-decoration:none'>study</span></a> by The Lancet found.<o:p></o:p></span></p><p style='mso-margin-top-alt:0cm;margin-right:0cm;margin-bottom:22.5pt;margin-left:0cm;line-height:106%;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit'><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black;mso-fareast-language:EN-US'>Even monthly testing across the U.S., requiring 12 million tests a day, would be more cost-effective than the current approach of testing only people with symptoms and their close contacts, the medical journal said.<o:p></o:p></span></p><h3 style='mso-margin-top-alt:9.25pt;margin-right:0cm;margin-bottom:9.25pt;margin-left:0cm;line-height:106%;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit' id=von-der-leyen-acknowledges-vaccinestrategy-flaw-150-pm-hk><b><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black'>Von der Leyen Acknowledges Vaccine-Strategy Flaw <o:p></o:p></span></b></h3><p style='mso-margin-top-alt:22.5pt;margin-right:0cm;margin-bottom:22.5pt;margin-left:0cm;line-height:106%;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit'><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black;mso-fareast-language:EN-US'>Ursula von der Leyen said she underestimated the complications that can arise in the production of coronavirus vaccines, Sueddeutsche Zeitung reported, citing an interview with the European Commission president.<o:p></o:p></span></p><p style='mso-margin-top-alt:22.5pt;margin-right:0cm;margin-bottom:22.5pt;margin-left:0cm;line-height:106%;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit'><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black;mso-fareast-language:EN-US'>“We focused very much on the development of a vaccine,” she said. “In retrospect, we should have thought more about the challenges of mass production in parallel.”<o:p></o:p></span></p><h3 style='mso-margin-top-alt:9.25pt;margin-right:0cm;margin-bottom:9.25pt;margin-left:0cm;line-height:106%;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit' id=celltrion-treatment-gets-conditional-approval-in-korea-126-pm-hk><b><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black'>Celltrion Treatment Gets Conditional Approval in Korea <o:p></o:p></span></b></h3><p style='margin:0cm;margin-bottom:.0001pt;line-height:106%;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit'><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black;mso-fareast-language:EN-US'>South Korea’s drug safety ministry <a href="https://www.bloomberg.com/news/terminal/QO1I7OT1UM1G" target="_blank" title="Celltrion’s Virus Treatment Gets Conditional Approval From Korea"><span style='color:black;border:none windowtext 1.0pt;padding:0cm;text-decoration:none'>approved</span></a> Celltrion’s Covid-19 treatment for high-risk patients with mild-to-moderate symptoms. The approval is under the condition that Celltrion submits results of its Phase 3 clinical trial.<br><br><o:p></o:p></span></p><h3 style='mso-margin-top-alt:9.25pt;margin-right:0cm;margin-bottom:9.25pt;margin-left:0cm;line-height:106%;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit' id=pfizer-withdraws-emergency-use-request-in-india-report-122-pm-hk><b><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black'>Pfizer Withdraws Emergency Use Request in India: Report <o:p></o:p></span></b></h3><p style='margin:0cm;margin-bottom:.0001pt;line-height:106%;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit'><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black;mso-fareast-language:EN-US'>Pfizer has <a href="https://www.bloomberg.com/news/terminal/QO1IRCDWLU6E" target="_blank" title="Pfizer Withdraws Vaccine Emergency Use Request in India: Reuters"><span style='color:black;border:none windowtext 1.0pt;padding:0cm;text-decoration:none'>withdrawn an application</span></a> for emergency-use authorization of its Covid-19 vaccine in India, Reuters reporter Krishna Das tweeted, citing an unidentified spokeswoman. Pfizer <span style='border:none windowtext 1.0pt;padding:0cm'>reportedly</span> made the decision after understanding what additional information India’s regulator requires.<br><br><o:p></o:p></span></p><h3 style='mso-margin-top-alt:9.25pt;margin-right:0cm;margin-bottom:9.25pt;margin-left:0cm;line-height:106%;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit' id=philippines-to-require-masks-in-all-vehicles-120-pm-hk><b><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black'>Philippines to Require Masks in All Vehicles </span></b><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black'><br><br>The Philippines will make it mandatory to wear masks inside all vehicles, even for passengers from the same household, the Transport and Health Departments said in a statement. Only drivers traveling alone may remove masks, while violators face fines, according to the statement.<o:p></o:p></span></h3><h3 style='mso-margin-top-alt:9.25pt;margin-right:0cm;margin-bottom:9.25pt;margin-left:0cm;line-height:106%;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit' id=brazil-in-talks-for-20-million-more-sinovac-shots-reuters-111-pm-hk><b><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black'>Brazil in Talks for 20 Million More Sinovac Shots: Reuters <o:p></o:p></span></b></h3><p style='margin:0cm;margin-bottom:.0001pt;line-height:106%;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit'><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black;mso-fareast-language:EN-US'>Brazil in talks to buy <a href="https://www.bloomberg.com/news/terminal/QO1I8ODWX2PT" target="_blank" title="Brazil in Talks to Buy Extra 20m Sinovac Vaccines: Reuters"><span style='color:black;border:none windowtext 1.0pt;padding:0cm;text-decoration:none'>20 million more doses</span></a> of the Sinovac Biotech coronavirus vaccine, Reuters reported, citing an interview with Sao Paulo governor Joao Doria. The order will be on top of 100 million vaccine doses secured by Butantan biomedical institute, Doria said.<o:p></o:p></span></p><h3 style='mso-margin-top-alt:9.25pt;margin-right:0cm;margin-bottom:9.25pt;margin-left:0cm;line-height:106%;background:white;vertical-align:baseline'><b><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black'><br>Valneva Eyes Head-to-Head Advanced Trial For Vaccine </span></b><b><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black'><o:p></o:p></span></b></h3><p style='margin:0cm;margin-bottom:.0001pt;line-height:106%;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit'><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black;mso-fareast-language:EN-US'>Valneva SE is looking at running a <a href="https://www.bloomberg.com/news/articles/2021-02-05/valneva-eyes-head-to-head-advanced-trial-for-covid-19-vaccine" target="_blank" title="Valneva Eyes Head-to-Head Advanced Trial For Covid-19 Vaccine"><span style='color:black;border:none windowtext 1.0pt;padding:0cm;text-decoration:none'>head-to-head trial</span></a> with an approved Covid-19 vaccine for advanced tests of its own shot in the U.K., where the rapid rollout of immunizations could make it hard to conduct a conventional study using a placebo.<o:p></o:p></span></p><p style='mso-margin-top-alt:0cm;margin-right:0cm;margin-bottom:22.5pt;margin-left:0cm;line-height:106%;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit'><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black;mso-fareast-language:EN-US'>The French pharmaceutical company is in discussions with regulators about whether volunteers in the control arm of the trial, planned to start in April, could be given a coronavirus shot that has already been authorized, Chief Executive Officer Thomas Lingelbach said. The company is planning to enroll about 4,000 people in its late-stage trials in the U.K. and aims for approval in the last quarter of 2021.<o:p></o:p></span></p><h3 style='mso-margin-top-alt:9.25pt;margin-right:0cm;margin-bottom:9.25pt;margin-left:0cm;line-height:106%;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit' id=uk-variant-found-in-melbourne-before-australian-open-1253-pm-hk><b><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black'>U.K. Variant Found in Melbourne Before Australian Open <o:p></o:p></span></b></h3><p style='margin:0cm;margin-bottom:.0001pt;line-height:106%;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit'><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black;mso-fareast-language:EN-US'>More than 500 members of the Australian Open tennis cohort received negative Covid-19 test results Friday after a quarantine hotel worker <a href="https://www.bloomberg.com/news/articles/2021-02-05/u-k-variant-found-in-melbourne-case-as-tennis-players-cleared" target="_blank" title="U.K. Variant Found in Melbourne Case as Tennis Players Cleared"><span style='color:black;border:none windowtext 1.0pt;padding:0cm;text-decoration:none'>contracted the virus</span></a>. Host city Melbourne had all but eliminated the virus until a local case of the B.1.1.7 variant was detected in a worker at a hotel where players quarantined.<o:p></o:p></span></p><p style='mso-margin-top-alt:22.5pt;margin-right:0cm;margin-bottom:22.5pt;margin-left:0cm;line-height:106%;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit'><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black;mso-fareast-language:EN-US'>The isolation for more than 24 hours of players, officials and support staff who were staying at the Grand Hyatt added to already disrupted preparation for the tournament, which begins Feb. 8.<o:p></o:p></span></p><h3 style='mso-margin-top-alt:9.25pt;margin-right:0cm;margin-bottom:9.25pt;margin-left:0cm;line-height:106%;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit' id=amlo-says-in-good-health-while-recovering-from-covid-1121-am-hk><b><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black'>AMLO Says in Good Health While Recovering From Covid <o:p></o:p></span></b></h3><p style='margin:0cm;margin-bottom:.0001pt;line-height:106%;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit'><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black;mso-fareast-language:EN-US'>Mexican President Andres Manuel Lopez Obrador said a Covid antigen test he took returned a <a href="https://www.bloomberg.com/news/terminal/QO1CSRT0G1L4" target="_blank" title="Mexico President Says He’s in Good Health, Recovering From Covid"><span style='color:black;border:none windowtext 1.0pt;padding:0cm;text-decoration:none'>negative result</span></a>. AMLO, as the president is commonly known, posted a video online saying he’s in good health as he <a href="https://www.bloomberg.com/news/articles/2021-01-30/mexico-s-amlo-says-critical-stage-of-his-covid-has-passed" target="_blank" title="Mexico’s AMLO Says ‘Critical Stage’ of His Covid Has Passed"><span style='color:black;border:none windowtext 1.0pt;padding:0cm;text-decoration:none'>recovers</span></a> from Covid-19.<br><br><o:p></o:p></span></p><h3 style='mso-margin-top-alt:9.25pt;margin-right:0cm;margin-bottom:9.25pt;margin-left:0cm;line-height:106%;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit' id=india-gets-lions-share-of-covax-shots-despite-tepid-demand-1032-am-hk><b><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black'>India Gets Lion’s Share of Covax Shots Despite Tepid Demand <o:p></o:p></span></b></h3><p style='margin:0cm;margin-bottom:.0001pt;line-height:106%;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit'><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black;mso-fareast-language:EN-US'>India is set to receive the <a href="https://www.bloomberg.com/news/articles/2021-02-05/india-gets-lion-s-share-of-covax-shots-despite-tepid-demand" target="_blank" title="India Gets Lion’s Share of Covax Shots Despite Tepid Demand"><span style='color:black;border:none windowtext 1.0pt;padding:0cm;text-decoration:none'>largest number</span></a>of Covid-19 vaccine doses -- 97.2 million shots -- in the first tranche of distribution from the World Health Organization’s Covax initiative, despite the fact that supply in the country currently appears to outstrip demand.<br><br>The Covax initiative, aimed at creating equitable global access to Covid vaccines especially for developing countries, is planning to distribute 337.2 million doses at the end of this month, the first delivery of some 2 billion shots it’s ordered so far.<br><br>According to an interim <a href="https://www.who.int/docs/default-source/coronaviruse/act-accelerator/covax/covax-interim-distribution-forecast.pdf?sfvrsn=7889475d_5" target="_blank" title="Click to view webpage."><span style='color:black;border:none windowtext 1.0pt;padding:0cm;text-decoration:none'>distribution forecast</span></a> published Wednesday, the second-biggest tranche of 17.2 million shots will go to Pakistan, followed by 16 million doses to Nigeria and 13.7 million to Indonesia. North Korea will receive 2 million shots.<o:p></o:p></span></p><p style='margin:0cm;margin-bottom:.0001pt;line-height:106%;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit'><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black;mso-fareast-language:EN-US'>The large allocation to India is likely to raise eyebrows given that the country currently seems to have plenty of shots, but few takers. Only around half of those eligible to get vaccinated in its inoculation drive have come forward, and local <span style='border:none windowtext 1.0pt;padding:0cm'>media reports</span> say that India producer Serum Institute of India is <a href="https://thewire.in/government/vaccination-drive-covishield-serum-institute-stockpile-lying-idle-government-procurement-pushing-covaxin" target="_blank" title="Click to view webpage."><span style='color:black;border:none windowtext 1.0pt;padding:0cm;text-decoration:none'>sitting</span></a> on over 55 million doses and has temporarily halted production.<br><br><o:p></o:p></span></p><h3 style='mso-margin-top-alt:9.25pt;margin-right:0cm;margin-bottom:9.25pt;margin-left:0cm;line-height:106%;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit' id=postcoup-myanmar-kicks-off-vaccination-drive-1012-am-hk><b><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black'>Post-Coup Myanmar Kicks Off Vaccination Drive <o:p></o:p></span></b></h3><p style='mso-margin-top-alt:22.5pt;margin-right:0cm;margin-bottom:22.5pt;margin-left:0cm;line-height:106%;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit'><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black;mso-fareast-language:EN-US'>Myanmar is set to kick off vaccination for the general public Friday, starting with townships with the highest number of infections and mortality rate, according to Khin Khin Gyi, director of emerging infectious disease at the Ministry of Health and Sports. The initial phase will prioritize those 65 and above.<o:p></o:p></span></p><p style='mso-margin-top-alt:22.5pt;margin-right:0cm;margin-bottom:22.5pt;margin-left:0cm;line-height:106%;background:white;vertical-align:baseline'><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black;mso-fareast-language:EN-US'>Myanmar’s military, which seized power in a coup earlier this week, has vowed to inoculate 38.4 million people 18 and older by the end of this year. The administration expects the first batch of 30 million doses of AstraZeneca vaccine ordered from the Serum Institute of India to arrive next week and 27 million doses from the Covax facility from March.<o:p></o:p></span></p><h3 style='mso-margin-top-alt:9.25pt;margin-right:0cm;margin-bottom:9.25pt;margin-left:0cm;line-height:106%;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit' id=tokyo-survey-shows-091-have-covid-antibodies-1003-am-hk><b><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black'>Tokyo Survey Shows 0.91% Have Covid Antibodies <o:p></o:p></span></b></h3><p style='margin:0cm;margin-bottom:.0001pt;line-height:106%;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit'><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black;mso-fareast-language:EN-US'>A <a href="https://www.mhlw.go.jp/content/000734482.pdf" target="_blank" title="Japan Covid survey"><span style='color:black;border:none windowtext 1.0pt;padding:0cm;text-decoration:none'>survey</span></a> conducted by Japan’s Health Ministry in December found 0.91% of people in Tokyo have Covid-19 antibodies, up from 0.1% in a June tally. The survey showed a rate of 0.58% in Osaka and 0.54% in Aichi prefecture.<o:p></o:p></span></p><h3 style='mso-margin-top-alt:9.25pt;margin-right:0cm;margin-bottom:9.25pt;margin-left:0cm;line-height:106%;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit' id=house-dems-to-meet-biden-after-senate-move-on-stimulus-933-am-hk><b><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black'>House Dems to Meet Biden After Senate Move on Stimulus <o:p></o:p></span></b></h3><p style='margin:0cm;margin-bottom:.0001pt;line-height:106%;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit'><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black;mso-fareast-language:EN-US'>Speaker Nancy Pelosi and other U.S. House of Representatives leaders will meet with President Joe Biden on Friday after the Senate backed by 99-1 a non-binding call to <a href="https://www.bloomberg.com/news/articles/2021-02-04/romney-proposes-expanding-child-tax-credit-stimulus-update" target="_blank" title="Pelosi, Other House Leaders to Meet With Biden: Stimulus Update"><span style='color:black;border:none windowtext 1.0pt;padding:0cm;text-decoration:none'>oppose stimulus checks</span></a> going to “upper-income taxpayers” -- part of the complex process of preparing Biden’s $1.9 trillion Covid-19 relief plan for passage through Congress.<o:p></o:p></span></p><p style='mso-margin-top-alt:0cm;margin-right:0cm;margin-bottom:22.5pt;margin-left:0cm;line-height:106%;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit'><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black;mso-fareast-language:EN-US'>The amendment to the fiscal 2021 budget resolution doesn’t define the income cutoff for stimulus checks, but serves as a test vote for senators to gauge support on tightening the requirements.<o:p></o:p></span></p><h3 style='mso-margin-top-alt:9.25pt;margin-right:0cm;margin-bottom:9.25pt;margin-left:0cm;line-height:106%;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit' id=fda-limits-emergency-use-authorization-for-plasma-911-am-hk><b><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black'>FDA Limits Emergency Use Authorization for Plasma <o:p></o:p></span></b></h3><p style='mso-margin-top-alt:22.5pt;margin-right:0cm;margin-bottom:22.5pt;margin-left:0cm;line-height:106%;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit'><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black;mso-fareast-language:EN-US'>The U.S. Food and Drug Administration revised its Emergency Use Authorization for convalescent plasma, limiting its use to hospitalized patients early in the disease. The convalescent plasma used must contain high levels of antibodies.<o:p></o:p></span></p><p style='mso-margin-top-alt:22.5pt;margin-right:0cm;margin-bottom:22.5pt;margin-left:0cm;line-height:106%;background:white;vertical-align:baseline'><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black;mso-fareast-language:EN-US'>The EUA was updated based on data from more recent clinical trials since the original order was issued in August, the agency said in a statement. The original authorization produced an embarrassing episode for then-FDA Commissioner Stephen Hahn, who had to walk back comments he made exaggerating the benefit of convalescent plasma. Plasma with low levels of antibodies has not been shown to be helpful in treating Covid-19 and is no longer authorized for use in treatment, the FDA said.<o:p></o:p></span></p><h3 style='mso-margin-top-alt:9.25pt;margin-right:0cm;margin-bottom:9.25pt;margin-left:0cm;line-height:106%;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit' id=canada-extends-cruiseship-ban-to-february-2022-903-am-hk><b><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black'>Canada Extends Cruise-Ship Ban to February 2022 <o:p></o:p></span></b></h3><p style='margin:0cm;margin-bottom:.0001pt;line-height:106%;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit'><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black;mso-fareast-language:EN-US'>Canada extended its <a href="https://www.bloomberg.com/news/articles/2021-02-05/canada-says-no-cruises-until-2022-shutting-down-alaska-trips" target="_blank" title="Canada Says No Cruises Until 2022, Shutting Down Alaska Trips"><span style='color:black;border:none windowtext 1.0pt;padding:0cm;text-decoration:none'>ban on cruise ships</span></a> through February 2022 because of Covid-19, effectively shutting down popular summer trips to Alaska for another year. The prohibition will allow authorities to focus on vaccine rollout and limit the spread of new variants, the government said in a statement.<o:p></o:p></span></p><p style='mso-margin-top-alt:22.5pt;margin-right:0cm;margin-bottom:22.5pt;margin-left:0cm;line-height:106%;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit'><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black;mso-fareast-language:EN-US'>The decision is a setback for an industry trying to get back in business after being in dry dock for almost a year. While Alaska is one of the industry’s top destinations, the ban will also affect New England cruises that travel north to Montreal and other stops.<o:p></o:p></span></p><h3 style='mso-margin-top-alt:9.25pt;margin-right:0cm;margin-bottom:9.25pt;margin-left:0cm;line-height:106%;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit' id=china-gets-northern-outbreak-under-control-850-am-hk><b><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black'>China Gets Northern Outbreak Under Control <o:p></o:p></span></b></h3><p style='mso-margin-top-alt:22.5pt;margin-right:0cm;margin-bottom:22.5pt;margin-left:0cm;line-height:106%;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit'><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black;mso-fareast-language:EN-US'>China appears to have controlled a virus resurgence in its northern regions, with new local cases reported at just six Friday, from 135 on Jan. 14. Overall, China’s winter wave -- concentrated in the provinces of Heilongjiang, Jilin and Hebei -- numbers more than 2,000 infections.<o:p></o:p></span></p><p style='mso-margin-top-alt:22.5pt;margin-right:0cm;margin-bottom:22.5pt;margin-left:0cm;line-height:106%;background:white;vertical-align:baseline'><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black;mso-fareast-language:EN-US'>While there were concerns that infections would seep into the Beijing ahead of Lunar New Year and national political meetings scheduled for March, the capital has recorded only 44 cases so far. Still, officials remain on high alert and have discouraged travel during the Lunar New Year holiday that starts Feb. 11, while tightening restrictions on people entering Beijing.<o:p></o:p></span></p><h3 style='mso-margin-top-alt:9.25pt;margin-right:0cm;margin-bottom:9.25pt;margin-left:0cm;line-height:106%;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit' id=uk-to-start-mandatory-quarantine-for-travelers-feb-15-815-am-hk><b><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black'>U.K. to Start Mandatory Quarantine for Travelers Feb. 15 <o:p></o:p></span></b></h3><p style='margin:0cm;margin-bottom:.0001pt;line-height:106%;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit'><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black;mso-fareast-language:EN-US'>The U.K. will require travelers from coronavirus hot spots to quarantine <a href="https://www.bloomberg.com/news/articles/2021-02-04/u-k-seeks-advice-from-australia-on-how-to-quarantine-travelers" target="_blank" title="U.K. to Start Mandatory Quarantine for Travelers on Feb. 15 (1)" id=14782><span style='color:black;border:none windowtext 1.0pt;padding:0cm;text-decoration:none'>starting Feb. 15</span></a>, the government said, adding flesh to a policy first announced last month.<o:p></o:p></span></p><p style='mso-margin-top-alt:0cm;margin-right:0cm;margin-bottom:22.5pt;margin-left:0cm;line-height:106%;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit'><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black;mso-fareast-language:EN-US'>Arrivals from countries on the U.K.’s travel ban list will be required to isolate for 10 days in government-approved accommodation, the Department for Health and Social Care said Thursday. The government is seeking bids from hotels near airports and ports to support the program.<o:p></o:p></span></p><h3 style='mso-margin-top-alt:9.25pt;margin-right:0cm;margin-bottom:9.25pt;margin-left:0cm;line-height:106%;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit' id=fda-says-variants-wont-mean-back-to-square-one-732-am-hk><b><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black'>FDA Says Variants Won’t Mean Back to Square One <o:p></o:p></span></b></h3><p style='mso-margin-top-alt:22.5pt;margin-right:0cm;margin-bottom:22.5pt;margin-left:0cm;line-height:106%;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit'><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black;mso-fareast-language:EN-US'>The U.S. Food and Drug Administration is working with industry to ensure that updated vaccines for Covid-19 variants are deployed as quickly as possible, Acting Commissioner Janet Woodcock said. The option of “streamlined” clinical trials for altered vaccines is under discussion, she said.<o:p></o:p></span></p><p style='mso-margin-top-alt:22.5pt;margin-right:0cm;margin-bottom:22.5pt;margin-left:0cm;line-height:106%;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit'><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black;mso-fareast-language:EN-US'>“We do not believe there will be the need to start at square one with any of these products,” Woodcock said. “We do not want to create obstacles to getting these tools to the frontlines.”<o:p></o:p></span></p><p style='mso-margin-top-alt:22.5pt;margin-right:0cm;margin-bottom:22.5pt;margin-left:0cm;line-height:106%;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit'><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black;mso-fareast-language:EN-US'>The FDA is building on experience with vaccines for other evolving infections diseases, such as the flu, she said.<o:p></o:p></span></p><h3 style='mso-margin-top-alt:9.25pt;margin-right:0cm;margin-bottom:9.25pt;margin-left:0cm;line-height:106%;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit' id=jj-seeks-emergency-vaccine-clearance-in-us-549-pm-ny><b><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black'>J&J Seeks Emergency Vaccine Clearance in U.S. <o:p></o:p></span></b></h3><p style='margin:0cm;margin-bottom:.0001pt;line-height:106%;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit'><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black;mso-fareast-language:EN-US'>Johnson & Johnson asked U.S. drug regulators to clear its experimental Covid-19 vaccine for <a href="https://www.bloomberg.com/news/articles/2021-02-04/j-j-seeks-emergency-clearance-for-covid-19-vaccine-in-u-s" target="_blank" title="J&J Seeks Vaccine Clearance, Moving U.S. Near Third Shot (1)"><span style='color:black;border:none windowtext 1.0pt;padding:0cm;text-decoration:none'>emergency use,</span></a> setting up what’s likely to be a fast-moving review process that could lead to millions more doses becoming available for the immunization drive within weeks.<o:p></o:p></span></p><p style='mso-margin-top-alt:22.5pt;margin-right:0cm;margin-bottom:22.5pt;margin-left:0cm;line-height:106%;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit'><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black;mso-fareast-language:EN-US'>The drugmaker said Thursday it had filed an application for emergency-use authorization with the U.S. Food and Drug Administration. The shot would give the U.S. a third vaccine to try to halt a pandemic that has killed more than 450,000 Americans.<o:p></o:p></span></p><p style='mso-margin-top-alt:22.5pt;margin-right:0cm;margin-bottom:22.5pt;margin-left:0cm;line-height:106%;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit'><span lang=EN-US style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:black;mso-fareast-language:EN-US'>The agency scheduled a Feb. 26 meeting where outside advisers will consider the request and make a recommendation about whether to grant it. While their decision isn’t binding, it would be unusual for the FDA to reject the experts’ advice.<o:p></o:p></span></p><p style='mso-margin-top-alt:22.5pt;margin-right:0cm;margin-bottom:22.5pt;margin-left:0cm;line-height:106%;background:white;vertical-align:baseline'><span style='font-size:11.0pt;line-height:106%;font-family:"Verdana",sans-serif;color:#222222'><o:p> </o:p></span></p></td><td width=6 style='width:4.4pt;border:none;padding:0cm 0cm 0cm 0cm;height:10.05pt'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'><o:p> </o:p></span></p></td></tr><tr style='height:10.05pt'><td width=6 style='width:4.4pt;border:none;padding:0cm 0cm 0cm 0cm;height:10.05pt'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'><o:p> </o:p></span></p></td></tr><tr style='height:10.05pt'><td width=6 style='width:4.4pt;border:none;padding:0cm 0cm 0cm 0cm;height:10.05pt'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'><o:p> </o:p></span></p></td></tr><tr style='height:10.05pt'><td width=910 colspan=4 valign=top style='width:682.8pt;border-top:none;border-left:solid white 1.0pt;border-bottom:none;border-right:solid white 1.0pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.05pt'><p class=MsoNormal style='text-indent:33.35pt;line-height:106%'><span lang=EN-US style='font-family:"Verdana",sans-serif;mso-fareast-language:EN-ZW'><o:p> </o:p></span></p><p class=MsoNormal style='line-height:106%'><span lang=EN-US style='font-family:"Verdana",sans-serif'><o:p> </o:p></span></p><p class=MsoNormal style='mso-margin-top-alt:auto;margin-left:36.0pt;line-height:115%;background:white'><b><span style='font-family:"Verdana",sans-serif;color:#222222;mso-fareast-language:EN-ZW'><o:p> </o:p></span></b></p></td><td width=6 style='width:4.4pt;border:none;padding:0cm 0cm 0cm 0cm;height:10.05pt'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'><o:p> </o:p></span></p></td></tr><tr><td width=910 colspan=4 style='width:682.8pt;border-top:none;border-left:solid white 1.0pt;border-bottom:none;border-right:solid white 1.0pt;background:#F2F2F2;padding:0cm 5.4pt 0cm 5.4pt'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'><o:p> </o:p></span></p><p class=MsoNormal style='line-height:105%'><strong><span lang=EN-US style='font-family:"Verdana",sans-serif;color:#345883'>INVESTORS DIARY 2021</span></strong><span lang=EN-US style='font-family:"Verdana",sans-serif'><o:p></o:p></span></p></td><td width=6 style='width:4.4pt;border:none;padding:0cm 0cm 0cm 0cm'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'> <o:p></o:p></span></p></td></tr><tr style='height:3.25pt'><td width=175 style='width:131.3pt;border-top:none;border-left:solid white 1.0pt;border-bottom:none;border-right:solid white 1.0pt;background:#F2F2F2;padding:0cm 5.4pt 0cm 5.4pt;height:3.25pt'><p class=MsoNormal style='text-indent:12.6pt;line-height:105%'><b><span lang=EN-US style='font-family:"Verdana",sans-serif'>Company</span></b><span lang=EN-US style='font-family:"Verdana",sans-serif'><o:p></o:p></span></p></td><td width=207 style='width:155.5pt;border:none;border-right:solid white 1.0pt;background:#F2F2F2;padding:0cm 5.4pt 0cm 5.4pt;height:3.25pt'><p class=MsoNormal style='line-height:105%'><b><span lang=EN-US style='font-family:"Verdana",sans-serif'>Event</span></b><span lang=EN-US style='font-family:"Verdana",sans-serif'><o:p></o:p></span></p></td><td width=353 style='width:264.7pt;border:none;border-right:solid white 1.0pt;background:#F2F2F2;padding:0cm 5.4pt 0cm 5.4pt;height:3.25pt'><p class=MsoNormal style='line-height:105%'><b><span lang=EN-US style='font-family:"Verdana",sans-serif'>Venue</span></b><span lang=EN-US style='font-family:"Verdana",sans-serif'><o:p></o:p></span></p></td><td width=175 valign=bottom style='width:131.3pt;border:none;border-right:solid white 1.0pt;background:#F2F2F2;padding:0cm 5.4pt 0cm 5.4pt;height:3.25pt'><p class=MsoNormal style='line-height:105%'><b><span lang=EN-US style='font-family:"Verdana",sans-serif'>Date & Time</span></b><span lang=EN-US style='font-family:"Verdana",sans-serif'><o:p></o:p></span></p></td><td width=6 style='width:4.4pt;border:none;padding:0cm 0cm 0cm 0cm;height:3.25pt'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'> <o:p></o:p></span></p></td></tr><tr style='height:3.25pt'><td width=175 valign=top style='width:131.3pt;border-top:none;border-left:solid white 1.0pt;border-bottom:none;border-right:solid white 1.0pt;background:#F2F2F2;padding:0cm 5.4pt 0cm 5.4pt;height:3.25pt'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'><o:p> </o:p></span></p></td><td width=207 style='width:155.5pt;border:none;border-right:solid white 1.0pt;background:#F2F2F2;padding:0cm 5.4pt 0cm 5.4pt;height:3.25pt'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'><o:p> </o:p></span></p></td><td width=353 style='width:264.7pt;border:none;border-right:solid white 1.0pt;background:#F2F2F2;padding:0cm 5.4pt 0cm 5.4pt;height:3.25pt'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'><o:p> </o:p></span></p></td><td width=175 valign=top style='width:131.3pt;border:none;border-right:solid white 1.0pt;background:#F2F2F2;padding:0cm 5.4pt 0cm 5.4pt;height:3.25pt'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'><o:p> </o:p></span></p></td><td width=6 style='width:4.4pt;border:none;padding:0cm 0cm 0cm 0cm;height:3.25pt'><p class=MsoNormal style='margin-left:72.0pt;text-indent:-72.0pt;line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'><o:p> </o:p></span></p></td></tr><tr style='height:3.25pt'><td width=175 valign=top style='width:131.3pt;border-top:none;border-left:solid white 1.0pt;border-bottom:none;border-right:solid white 1.0pt;background:#F2F2F2;padding:0cm 5.4pt 0cm 5.4pt;height:3.25pt'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'><o:p> </o:p></span></p></td><td width=207 style='width:155.5pt;border:none;border-right:solid white 1.0pt;background:#F2F2F2;padding:0cm 5.4pt 0cm 5.4pt;height:3.25pt'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'><o:p> </o:p></span></p></td><td width=353 style='width:264.7pt;border:none;border-right:solid white 1.0pt;background:#F2F2F2;padding:0cm 5.4pt 0cm 5.4pt;height:3.25pt'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'><o:p> </o:p></span></p></td><td width=175 valign=top style='width:131.3pt;border:none;border-right:solid white 1.0pt;background:#F2F2F2;padding:0cm 5.4pt 0cm 5.4pt;height:3.25pt'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'><o:p> </o:p></span></p></td><td width=6 style='width:4.4pt;border:none;padding:0cm 0cm 0cm 0cm;height:3.25pt'><p class=MsoNormal style='margin-left:72.0pt;text-indent:-72.0pt;line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'><o:p> </o:p></span></p></td></tr><tr style='height:3.25pt'><td width=382 colspan=2 valign=top style='width:286.8pt;border-top:none;border-left:solid white 1.0pt;border-bottom:none;border-right:solid white 1.0pt;background:#D9D9D9;padding:0cm 5.4pt 0cm 5.4pt;height:3.25pt'><p class=MsoBodyText style='margin:0cm;margin-bottom:.0001pt;line-height:105%'><b><span lang=EN-US style='font-size:11.0pt;line-height:105%;font-family:"Verdana",sans-serif;color:black'>Companies under Cautionary<o:p></o:p></span></b></p></td><td width=353 style='width:264.7pt;border:none;border-right:solid white 1.0pt;background:#D9D9D9;padding:0cm 5.4pt 0cm 5.4pt;height:3.25pt'><p class=MsoBodyText style='margin:0cm;margin-bottom:.0001pt;line-height:105%'><b><span lang=EN-US style='font-size:11.0pt;line-height:105%;font-family:"Verdana",sans-serif;color:black'><o:p> </o:p></span></b></p></td><td width=175 valign=bottom style='width:131.3pt;border:none;border-right:solid white 1.0pt;background:#D9D9D9;padding:0cm 5.4pt 0cm 5.4pt;height:3.25pt'><p class=MsoBodyText style='margin:0cm;margin-bottom:.0001pt;line-height:105%'><b><span lang=EN-US style='font-size:11.0pt;line-height:105%;font-family:"Verdana",sans-serif;color:black'><o:p> </o:p></span></b></p></td><td width=6 style='width:4.4pt;border:none;padding:0cm 0cm 0cm 0cm;height:3.25pt'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'><o:p> </o:p></span></p></td></tr><tr style='height:3.25pt'><td width=382 colspan=2 valign=top style='width:286.8pt;border-top:none;border-left:solid white 1.0pt;border-bottom:none;border-right:solid white 1.0pt;background:#F2F2F2;padding:0cm 5.4pt 0cm 5.4pt;height:3.25pt'><p class=MsoBodyText style='margin:0cm;margin-bottom:.0001pt;line-height:105%'><span lang=EN-US style='font-size:11.0pt;line-height:105%;font-family:"Verdana",sans-serif'><o:p> </o:p></span></p></td><td width=353 style='width:264.7pt;border:none;border-right:solid white 1.0pt;background:#F2F2F2;padding:0cm 5.4pt 0cm 5.4pt;height:3.25pt'><p class=MsoBodyText style='margin:0cm;margin-bottom:.0001pt;line-height:105%'><span lang=EN-US style='font-size:11.0pt;line-height:105%;font-family:"Verdana",sans-serif'><o:p> </o:p></span></p></td><td width=175 valign=bottom style='width:131.3pt;border:none;border-right:solid white 1.0pt;background:#F2F2F2;padding:0cm 5.4pt 0cm 5.4pt;height:3.25pt'><p class=MsoBodyText style='margin:0cm;margin-bottom:.0001pt;line-height:105%'><span lang=EN-US style='font-size:11.0pt;line-height:105%;font-family:"Verdana",sans-serif'><o:p> </o:p></span></p></td><td width=6 style='width:4.4pt;border:none;padding:0cm 0cm 0cm 0cm;height:3.25pt'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'><o:p> </o:p></span></p></td></tr><tr style='height:3.25pt'><td width=382 colspan=2 valign=top style='width:286.8pt;border-top:none;border-left:solid white 1.0pt;border-bottom:none;border-right:solid white 1.0pt;background:#F2F2F2;padding:0cm 5.4pt 0cm 5.4pt;height:3.25pt'><p class=MsoBodyText style='margin:0cm;margin-bottom:.0001pt;line-height:105%'><span lang=EN-US style='font-size:11.0pt;line-height:105%;font-family:"Verdana",sans-serif'>ART<o:p></o:p></span></p></td><td width=353 style='width:264.7pt;border:none;border-right:solid white 1.0pt;background:#F2F2F2;padding:0cm 5.4pt 0cm 5.4pt;height:3.25pt'><p class=MsoBodyText style='margin:0cm;margin-bottom:.0001pt;line-height:105%'><span lang=EN-US style='font-size:11.0pt;line-height:105%;font-family:"Verdana",sans-serif'>PPC<o:p></o:p></span></p></td><td width=175 valign=bottom style='width:131.3pt;border:none;border-right:solid white 1.0pt;background:#F2F2F2;padding:0cm 5.4pt 0cm 5.4pt;height:3.25pt'><p class=MsoBodyText style='margin:0cm;margin-bottom:.0001pt;line-height:105%'><span lang=EN-US style='font-size:11.0pt;line-height:105%;font-family:"Verdana",sans-serif'>Dairibord<o:p></o:p></span></p></td><td width=6 style='width:4.4pt;border:none;padding:0cm 0cm 0cm 0cm;height:3.25pt'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'> <o:p></o:p></span></p></td></tr><tr style='height:3.25pt'><td width=382 colspan=2 valign=top style='width:286.8pt;border-top:none;border-left:solid white 1.0pt;border-bottom:none;border-right:solid white 1.0pt;background:#F2F2F2;padding:0cm 5.4pt 0cm 5.4pt;height:3.25pt'><p class=MsoBodyText style='margin:0cm;margin-bottom:.0001pt;line-height:105%'><span lang=EN-US style='font-size:11.0pt;line-height:105%;font-family:"Verdana",sans-serif'>Starafrica<o:p></o:p></span></p></td><td width=353 style='width:264.7pt;border:none;border-right:solid white 1.0pt;background:#F2F2F2;padding:0cm 5.4pt 0cm 5.4pt;height:3.25pt'><p class=MsoBodyText style='margin:0cm;margin-bottom:.0001pt;line-height:105%'><span lang=EN-US style='font-size:11.0pt;line-height:105%;font-family:"Verdana",sans-serif'>Fidelity<o:p></o:p></span></p></td><td width=175 valign=bottom style='width:131.3pt;border:none;border-right:solid white 1.0pt;background:#F2F2F2;padding:0cm 5.4pt 0cm 5.4pt;height:3.25pt'><p class=MsoBodyText style='margin:0cm;margin-bottom:.0001pt;line-height:105%'><span lang=EN-US style='font-size:11.0pt;line-height:105%;font-family:"Verdana",sans-serif'>Turnall<o:p></o:p></span></p></td><td width=6 style='width:4.4pt;border:none;padding:0cm 0cm 0cm 0cm;height:3.25pt'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'><o:p> </o:p></span></p></td></tr><tr style='height:3.25pt'><td width=382 colspan=2 valign=top style='width:286.8pt;border-top:none;border-left:solid white 1.0pt;border-bottom:none;border-right:solid white 1.0pt;background:#F2F2F2;padding:0cm 5.4pt 0cm 5.4pt;height:3.25pt'><p class=MsoBodyText style='margin:0cm;margin-bottom:.0001pt;line-height:105%'><span lang=EN-US style='font-size:11.0pt;line-height:105%;font-family:"Verdana",sans-serif'>Medtech<o:p></o:p></span></p></td><td width=353 style='width:264.7pt;border:none;border-right:solid white 1.0pt;background:#F2F2F2;padding:0cm 5.4pt 0cm 5.4pt;height:3.25pt'><p class=MsoBodyText style='margin:0cm;margin-bottom:.0001pt;line-height:105%'><span lang=EN-US style='font-size:11.0pt;line-height:105%;font-family:"Verdana",sans-serif'>Zimre<o:p></o:p></span></p></td><td width=175 valign=bottom style='width:131.3pt;border:none;border-right:solid white 1.0pt;background:#F2F2F2;padding:0cm 5.4pt 0cm 5.4pt;height:3.25pt'><p class=MsoBodyText style='margin:0cm;margin-bottom:.0001pt;line-height:105%'><span lang=EN-US style='font-size:11.0pt;line-height:105%;font-family:"Verdana",sans-serif'>Nampak Zimbabwe<o:p></o:p></span></p></td><td width=6 style='width:4.4pt;border:none;padding:0cm 0cm 0cm 0cm;height:3.25pt'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'><o:p> </o:p></span></p></td></tr><tr><td width=910 colspan=4 valign=top style='width:682.8pt;border-top:none;border-left:solid white 1.0pt;border-bottom:none;border-right:solid white 1.0pt;background:#1F497D;padding:0cm 5.4pt 0cm 5.4pt'><p class=MsoNormal style='line-height:105%'><i><span lang=EN-US style='font-family:"Verdana",sans-serif'><o:p> </o:p></span></i></p></td><td width=6 style='width:4.4pt;border:none;padding:0cm 0cm 0cm 0cm'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'> <o:p></o:p></span></p></td></tr><tr><td width=910 colspan=4 valign=top style='width:682.8pt;border-top:none;border-left:solid white 1.0pt;border-bottom:none;border-right:solid white 1.0pt;background:#1F497D;padding:0cm 5.4pt 0cm 5.4pt'><p class=MsoNormal style='line-height:105%'><i><span lang=EN-US style='font-size:8.0pt;line-height:105%;font-family:"Verdana",sans-serif;color:white'>DISCLAIMER: This report has been prepared by Bulls ‘n Bears, a division of Faith Capital (Pvt) Ltd for general information purposes only and does not constitute an offer to sell or the solicitation of an offer to buy or subscribe for any securities. The information contained in this report has been compiled from sources believed to be reliable, but no representation or warranty is made or guarantee given as to its accuracy or completeness. All opinions expressed and recommendations made are subject to change without notice. Securities or financial instruments mentioned herein may not be suitable for all investors. Securities of emerging and mid-size growth companies typically involve a higher degree of risk and more volatility than the securities of more established companies. Neither Faith Capital nor any other member of Bulls ‘n Bears nor any other person, accepts any liability whatsoever for any loss howsoever arising from any use of this report or its contents or otherwise arising in connection therewith. Recipients of this report shall be solely responsible for making their own independent investigation into the business, financial condition and future prospects of any companies referred to in this report. Other Indices quoted herein are for guideline purposes only and sourced from third parties.</span></i><i><span lang=EN-US style='font-size:8.0pt;line-height:105%;font-family:"Verdana",sans-serif'><o:p></o:p></span></i></p></td><td width=6 style='width:4.4pt;border:none;padding:0cm 0cm 0cm 0cm'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'> <o:p></o:p></span></p></td></tr><tr><td width=910 colspan=4 valign=top style='width:682.8pt;border-top:none;border-left:solid white 1.0pt;border-bottom:none;border-right:solid white 1.0pt;background:#F2F2F2;padding:0cm 5.4pt 0cm 5.4pt'><p class=MsoNormal style='line-height:105%'><i><span lang=EN-GB style='font-size:8.0pt;line-height:105%;font-family:"Verdana",sans-serif;color:white'><o:p> </o:p></span></i></p></td><td width=6 style='width:4.4pt;border:none;padding:0cm 0cm 0cm 0cm'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'> <o:p></o:p></span></p></td></tr><tr><td width=910 colspan=4 valign=top style='width:682.8pt;border-top:none;border-left:solid white 1.0pt;border-bottom:none;border-right:solid white 1.0pt;background:#F2F2F2;padding:0cm 5.4pt 0cm 5.4pt'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-size:8.0pt;line-height:105%;font-family:"Verdana",sans-serif'>(c) 2021 <b>Web</b>:<a href="http://www.bullszimbabwe.com"><span style='color:black;text-decoration:none'> www.bullszimbabwe.com </span></a><b>Email:</b> <a href="mailto:info@bulls.co.zw"><span style='color:black;text-decoration:none'>info@bulls.co.zw</span></a> <b>Tel:</b> +263 4 2927658 <b>Cell:</b> +263 77 344 1674<o:p></o:p></span></p></td><td width=6 style='width:4.4pt;border:none;padding:0cm 0cm 0cm 0cm'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'> <o:p></o:p></span></p></td></tr><tr><td width=910 colspan=4 valign=bottom style='width:682.8pt;border-top:none;border-left:solid white 1.0pt;border-bottom:none;border-right:solid white 1.0pt;background:#F2F2F2;padding:0cm 5.4pt 0cm 5.4pt'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-size:8.0pt;line-height:105%;font-family:"Verdana",sans-serif'><o:p> </o:p></span></p></td><td width=6 style='width:4.4pt;border:none;padding:0cm 0cm 0cm 0cm'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'> <o:p></o:p></span></p></td></tr></table></div><p class=MsoNormal><span lang=EN-US style='font-family:"Verdana",sans-serif'><o:p> </o:p></span></p><p class=MsoNormal><span lang=EN-US style='font-family:"Verdana",sans-serif'><o:p> </o:p></span></p><p class=MsoNormal><span lang=EN-US style='font-family:"Verdana",sans-serif'><o:p> </o:p></span></p><p class=MsoNormal><span lang=EN-US style='font-family:"Verdana",sans-serif'><o:p> </o:p></span></p></div></body></html>